A Phase 3, Single-Arm, Multiple-Dose, Pharmacokinetic Comparability Trial Between TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.
Datos básicos
Documentos
- No hay documentos
Participantes
Grupos
Financiadores - Promotores
Takeda Development Center Americas (TDCA)
Cita
A Phase 3, Single-Arm, Multiple-Dose, Pharmacokinetic Comparability Trial Between TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy. (TAK-881-3003). Takeda Development Center Americas (TDCA). 2025-2028. IP:TERESA SEVILLA MANTECÓN.
Portal de investigación